Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: METASTATIC MELANOMA, . Treffer: 68

2023

Ascierto, PA; Mandalà, M; Ferrucci, PF; Guidoboni, M; Rutkowski, P; Ferraresi, V; Arance, A; Guida, M; Maiello, E; Gogas, H; Richtig, E; Fierro, MT; Lebbè, C; Helgadottir, H; Queirolo, P; Spagnolo, F; Tucci, M; Del, Vecchio, M; Gonzales, Cao, M; Minisini, AM; De, Placido, S; Sanmamed, MF; Mallardo, D; Curvietto, M; Melero, I; Palmieri, G; Grimaldi, AM; Giannarelli, D; Dummer, R; Chiarion, Sileni, V Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
J Clin Oncol. 2023; 41(2): 212-221. Doi: 10.1200/JCO.21.02961
Web of Science PubMed FullText FullText_MUG

 

2021

Berger, M; Thueringer, A; Franz, D; Dandachi, N; Talakić, E; Richtig, G; Richtig, E; Rohrer, PM; Koch, L; Wolf, IH; Koch, C; Rainer, BM; Koeller, M; Pichler, M; Gerritsmann, H; Kashofer, K; Aigelsreiter, A Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing-A Prospective Feasibility Study.
Cancers (Basel). 2021; 13(12): Doi: 10.3390/cancers13123101 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Grbčić, P; Eichmann, TO; Kraljević, Pavelić, S; Sedić, M The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
Int J Mol Sci. 2021; 22(19): Doi: 10.3390/ijms221910767 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Kretschmer, N; Hufner, A; Durchschein, C; Popodi, K; Rinner, B; Lohberger, B; Bauer, R Synthesis and Pharmacological In Vitro Investigations of Novel Shikonin Derivatives with a Special Focus on Cyclopropane Bearing Derivatives.
Int J Mol Sci. 2021; 22(5): Doi: 10.3390/ijms22052774 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

van Akkooi, ACJ; Haferkamp, S; Papa, S; Franke, V; Pinter, A; Weishaupt, C; Huber, MA; Loquai, C; Richtig, E; Gokani, P; Öhrling, K; Louie, KS; Mohr, P A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries.
Adv Ther. 2021; Doi: 10.1007/s12325-020-01590-w [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Wagner, NB; Lenders, MM; Kühl, K; Reinhardt, L; André, F; Dudda, M; Ring, N; Ebel, C; Stäger, R; Zellweger, C; Lang, R; Paar, M; Gussek, P; Richtig, G; Stürmer, SH; Kimeswenger, S; Oellinger, A; Forschner, A; Leiter, U; Weide, B; Gassenmaier, M; Schraag, A; Klumpp, B; Hoetzenecker, W; Berking, C; Richtig, E; Ziemer, M; Mangana, J; Terheyden, P; Loquai, C; Nguyen, VA; Gebhardt, C; Meier, F; Diem, S; Cozzio, A; Flatz, L; Röcken, M; Garbe, C; Eigentler, TK Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
J Immunother Cancer. 2021; 9(5): e002350 Doi: 10.1136/jitc-2021-002350 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2020

Dummer, R; Lebbé, C; Atkinson, V; Mandalà, M; Nathan, PD; Arance, A; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HA; Ascierto, PA; Ribas, A; Flaherty, KT; Pakhle, N; Campbell, CD; Gusenleitner, D; Masood, A; Brase, JC; Gasal, E; Long, GV Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Nat Med. 2020; 26(10): 1557-1563. Doi: 10.1038/s41591-020-1082-2
Web of Science PubMed FullText FullText_MUG

 

2019

Weide, B; Eigentler, T; Catania, C; Ascierto, PA; Cascinu, S; Becker, JC; Hauschild, A; Romanini, A; Danielli, R; Dummer, R; Trefzer, U; Elia, G; Neri, D; Garbe, C A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Cancer Immunol Immunother. 2019; 68(9):1547-1559 Doi: 10.1007/s00262-019-02383-z
Web of Science PubMed FullText FullText_MUG

 

2018

Richtig, G; Hoeller, C; Wolf, M; Wolf, I; Rainer, BM; Schulter, G; Richtig, M; Grübler, MR; Gappmayer, A; Haidn, T; Kofler, J; Huegel, R; Lange-Asschenfeldt, B; Pichler, M; Pilz, S; Heinemann, A; Richtig, E Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.
PLoS One. 2018; 13(10):e0204729-e0204729 Doi: 10.1371/journal.pone.0204729 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2017

Kandolf Sekulovic, L; Peris, K; Hauschild, A; Stratigos, A; Grob, JJ; Nathan, P; Dummer, R; Forsea, AM; Hoeller, C; Gogas, H; Demidov, L; Lebbe, C; Blank, C; Olah, J; Bastholt, L; Herceg, D; Neyns, B; Vieira, R; Hansson, J; Rutkowski, P; Krajsova, I; Bylaite-Bucinskiene, M; Zalaudek, I; Maric-Brozic, J; Babovic, N; Banjin, M; Putnik, K; Weinlich, G; Todorovic, V; Kirov, K; Ocvirk, J; Zhukavets, A; Kukushkina, M; De La Cruz Merino, L; Ymeri, A; Risteski, M; Garbe, C More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
Eur J Cancer. 2017; 75(4):313-322 Doi: 10.1016/j.ejca.2017.01.012
Web of Science PubMed FullText FullText_MUG

 

Richtig, G; Ehall, B; Richtig, E; Aigelsreiter, A; Gutschner, T; Pichler, M Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.
Int J Mol Sci. 2017; 18(4): Doi: 10.3390/ijms18040715 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Ugurel, S; Loquai, C; Terheyden, P; Schadendorf, D; Richtig, E; Utikal, J; Gutzmer, R; Rass, K; Sunderkotter, C; Stein, A; Fluck, M; Kaatz, M; Trefzer, U; Kahler, K; Stadler, R; Berking, C; Holler, C; Kerschke, L; Edler, L; Kopp-Schneider, A; Becker, JC Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial
ONCOTARGET. 2017; 8(44): 76029-76043. Doi: 10.18632/oncotarget.18635 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Busam, KJ; Vilain, RE; Lum, T; Busam, JA; Hollmann, TJ; Saw, RP; Coit, DC; Scolyer, RA; Wiesner, T Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.
Am J Surg Pathol. 2016; 40(6):786-795 Doi: 10.1097/PAS.0000000000000611 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Hügel, R; Muendlein, A; Volbeding, L; Drexel, H; Richtig, E; Wehkamp, U; Painsi, C; Lange-Asschenfeldt, B; Hauschild, A; Egberts, F Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma.
Melanoma Res. 2016; 26(4):354-360 Doi: 10.1097/CMR.0000000000000269
Web of Science PubMed FullText FullText_MUG

 

Partl, R; Fastner, G; Kaiser, J; Kronhuber, E; Cetin-Strohmer, K; Steffal, C; Böhmer-Breitfelder, B; Mayer, J; Avian, A; Berghold, A KPS/LDH index: a simple tool for identifying patients with metastatic melanoma who are unlikely to benefit from palliative whole brain radiotherapy.
Support Care Cancer. 2016; 24(2):523-528 Doi: 10.1007/s00520-015-2793-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Richtig, G; Aigelsreiter, A; Kashofer, K; Talakic, E; Kupsa, R; Schaider, H; Richtig, E Two Case Reports of Rare BRAF Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options.
Case Rep Oncol. 2016; 9(3):543-546 Doi: 10.1159/000449125 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Trapp, EM; Trapp, M; Avian, A; Rohrer, PM; Weissenböck, T; Kapfhammer, HP; Demel, U; Linder, MD; Kresse, A; Richtig, E Association of Stress Coping Strategies with Immunological Parameters in Melanoma Patients.
ACTA DERM-VENEREOL. 2016; 96(217): 74-77. Doi: 10.2340/00015555-2372 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Willmes, C; Kumar, R; Becker, JC; Fried, I; Rachakonda, PS; Poppe, LM; Hesbacher, S; Schadendorf, D; Sucker, A; Schrama, D; Ugurel, S SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma.
Oncotarget. 2016; 7(9): 10117-10132. Doi: 10.18632/oncotarget.6956 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2015

Køllgaard, T; Ugurel-Becker, S; Idorn, M; Andersen, MH; Becker, JC; Straten, PT Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes.
PLoS One. 2015; 10(7):e0131934-e0131934 Doi: 10.1371/journal.pone.0131934 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Machan, S; El Shabrawi-Caelen, L; Nikolay, E; Kerl, H; Requena, L; Cerroni, L Follicular malignant melanoma: primary follicular or folliculotropic?
Am J Dermatopathol. 2015; 37(1):15-19 Doi: 10.1097/DAD.0000000000000087 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Piana, S; Tagliavini, E; Ragazzi, M; Zanelli, M; Zalaudek, I; Ciarrocchi, A; Valli, R Lymph node melanocytic nevi: pathogenesis and differential diagnoses, with special reference to p16 reactivity.
Pathol Res Pract. 2015; 211(5):381-388 Doi: 10.1016/j.prp.2015.01.003
Web of Science PubMed FullText FullText_MUG

 

Ugurel, S; Loquai, C; Kähler, K; Hassel, J; Berking, C; Zimmer, L; Haubitz, I; Satzger, I; Müller-Brenne, T; Mikhaimer, NC; Becker, JC; Kilian, KJ; Schadendorf, D; Heinzerling, L; Kaatz, M; Utikal, J; Göppner, D; Pföhler, C; Pflugfelder, A; Mössner, R; Gutzmer, R; Dermatologic Cooperative Oncology Group (DeCOG) A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.
Ann Oncol. 2015; 26(3):573-582 Doi: 10.1093/annonc/mdu573 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Goldinger, SM; Zimmer, L; Schulz, C; Ugurel, S; Hoeller, C; Kaehler, KC; Schadendorf, D; Hassel, JC; Becker, J; Hauschild, A; Dummer, R; Dermatology Cooperative Oncology Group (DeCOG) Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Eur J Cancer. 2014; 50(2):406-410 Doi: 10.1016/j.ejca.2013.09.014
Web of Science PubMed FullText FullText_MUG

 

Richtig, G; Richtig, E; Massone, C; Hofmann-Wellenhof, R Analysis of clinical, dermoscopic and histopathological features of primary melanomas of patients with metastatic disease--a retrospective study at the Department of Dermatology, Medical University of Graz, 2000-2010.
J Eur Acad Dermatol Venereol. 2014; 28(12):1776-1781 Doi: 10.1111/jdv.12413
Web of Science PubMed FullText FullText_MUG

 

2013

Degen, A; Weichenthal, M; Ugurel, S; Trefzer, U; Kilian, K; Garbe, C; Egberts, F; Poppe, LM; Hauschild, A; Gutzmer, R Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
J Dtsch Dermatol Ges. 2013; 11(9):846-853 Doi: 10.1111/ddg.12100
Web of Science PubMed FullText FullText_MUG

 

2012

Liu, SJ; Tetzlaff, MT; Liu, AH; Liegl-Atzwanger, B; Guo, J; Xu, XW; Loss of microRNA-205 expression is associated with melanoma progression.
Lab Invest. 2012; 92(7):1084-1096 Doi: 10.1038/labinvest.2012.62 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Egberts, F; Gutzmer, R; Ugurel, S; Becker, JC; Trefzer, U; Degen, A; Schenck, F; Frey, L; Wilhelm, T; Hassel, JC; Schadendorf, D; Livingstone, E; Mauch, C; Garbe, C; Berking, C; Rass, K; Mohr, P; Kaehler, KC; Weichenthal, M; Hauschild, A Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Ann Oncol. 2011; 22(7):1667-1674 Doi: 10.1093/annonc/mdq648 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Ugurel, S; Becker, JC [Treatment of advanced metastatic melanoma].
Hautarzt. 2011; 62(6):423-429 Doi: 10.1007/s00105-010-2041-5
Web of Science PubMed FullText FullText_MUG

 

2008

Giacomel, J; Zalaudek, I; Mordente, I; Nicolino, R; Argenziano, G Never perform laser treatment of skin tumors with clinical EFG criteria.
J Dtsch Dermatol Ges. 2008; 6(5):386-388 Doi: 10.1111/j.1610-0387.2007.06592.x (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Hauschild, A; Dummer, R; Ugurel, S; Kaehler, KC; Egberts, F; Fink, W; Both-Skalsky, J; Laetsch, B; Schadendorf, D Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
Cancer. 2008; 113(6):1404-1411 Doi: 10.1002/cncr.23722 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hauschild, A; Trefzer, U; Garbe, C; Kaehler, KC; Ugurel, S; Kiecker, F; Eigentler, T; Krissel, H; Schott, A; Schadendorf, D Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Melanoma Res. 2008; 18(4):274-278 Doi: 10.1097/CMR.0b013e328307c248
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Spieth, K; Kaufmann, R; Dummer, R; Garbe, C; Becker, JC; Hauschild, A; Tilgen, W; Ugurel, S; Beyeler, M; Bröcker, EB; Kaehler, KC; Pföhler, C; Gille, J; Leiter, U; Schadendorf, D Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Ann Oncol. 2008; 19(4):801-806 Doi: 10.1093/annonc/mdm565 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2007

Matharoo-Ball, B; Ratcliffe, L; Lancashire, L; Ugurel, S; Miles, AK; Weston, DJ; Rees, R; Schadendorf, D; Ball, G; Creaser, CS Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach.
Proteomics Clin Appl. 2007; 1(6):605-620 Doi: 10.1002/prca.200700022
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Seidl, H; Richtig, E; Tilz, H; Stefan, M; Schmidbauer, U; Asslaber, M; Zatloukal, K; Herlyn, M; Schaider, H Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma.
Hum Pathol. 2007; 38(5):768-780 Doi: 10.1016/j.humpath.2006.11.013
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2006

Hoek, KS; Schlegel, NC; Brafford, P; Sucker, A; Ugurel, S; Kumar, R; Weber, BL; Nathanson, KL; Phillips, DJ; Herlyn, M; Schadendorf, D; Dummer, R Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 2006; 19(4):290-302 Doi: 10.1111/j.1600-0749.2006.00322.x
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Schadendorf, D; Hauschild, A; Ugurel, S; Thoelke, A; Egberts, F; Kreissig, M; Linse, R; Trefzer, U; Vogt, T; Tilgen, W; Mohr, P; Garbe, C Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Ann Oncol. 2006; 17(10):1592-1597 Doi: 10.1093/annonc/mdl148 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Thoelke, A; Schmid, HP; Figl, R; Schadendorf, D; Ugurel, S Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanoma.
Eur J Dermatol. 2006; 16(4):428-430 (- Case Report) [OPEN ACCESS]
Web of Science PubMed Google Scholar

 

2005

Kaufmann, R; Spieth, K; Leiter, U; Mauch, C; von den Driesch, P; Vogt, T; Linse, R; Tilgen, W; Schadendorf, D; Becker, JC; Sebastian, G; Krengel, S; Kretschmer, L; Garbe, C; Dummer, R Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
J Clin Oncol. 2005; 23(35):9001-9007 Doi: 10.1200/JCO.2005.01.1551 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Richtig, E; Ludwig, R; Kerl, H; Smolle, J Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
BRIT J DERMATOL. 2005; 153(5): 925-931. Doi: 10.1111/j.1365-2133.2005.06796.x
Web of Science PubMed FullText FullText_MUG

 

Richtig, E; Soyer, HP; Posch, M; Mossbacher, U; Bauer, P; Teban, L; Svolba, G; Wolf, IH; Fritsch, P; Zelger, B; Volc-Platzer, B; Gebhart, W; Mischer, P; Steiner, A; Pachinger, W; Hintner, H; Gschnait, F; Rappersberger, K; Pilarski, P; Pehamberger, H; European Cooperative Adjuvant Melanoma Treatment Study Group Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
J Clin Oncol. 2005; 23(34):8655-8663 Doi: 10.1200/JCO.2004.00.8128 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Ugurel, S; Hildenbrand, R; Zimpfer, A; La Rosee, P; Paschka, P; Sucker, A; Keikavoussi, P; Becker, JC; Rittgen, W; Hochhaus, A; Schadendorf, D Lack of clinical efficacy of imatinib in metastatic melanoma.
Br J Cancer. 2005; 92(8):1398-1405 Doi: 10.1038/sj.bjc.6602529 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

Vetter, CS; Muller-Blech, K; Schrama, D; Brocker, EB; Becker, JC Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions.
Arch Dermatol Res. 2005; 297(1):26-30 Doi: 10.1007/s00403-005-0572-x
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2004

Andersen, MH; Fensterle, J; Ugurel, S; Reker, S; Houben, R; Guldberg, P; Berger, TG; Schadendorf, D; Trefzer, U; Brocker, EB; Straten, PT; Rapp, UR; Becker, JC Immunogenicity of constitutively active (V599E)BRaf
CANCER RES. 2004; 64(15): 5456-5460. Doi: 10.1158/0008-5472.CAN-04-0937 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

de Giorgi, V; Massi, D; Brunasso, G; Salvini, C; Mastrolorenzo, A; Zuccati, G; Carli, P Eruptive multiple blue nevi of the penis: a clinical dermoscopic pathologic case study.
J Cutan Pathol. 2004; 31(2):185-188 Doi: 10.1111/j.0303-6987.2004.00153.x (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Helige, C; Hofmann-Wellenhof, R; Fink-Puches, R; Smolle, J Mofarotene-induced inhibition of melanoma cell motility by increasing vinculin-containing focal contacts.
MELANOMA RES. 2004; 14(6): 547-554. Doi: 10.1097%2F00008390-200412000-00018
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Richtig, E; Hofmann-Wellenhof, R; Pehamberger, H; Forstinger, Ch; Wolff, K; Mischer, P; Raml, J; Fritsch, P; Zelger, B; Ratzinger, G; Koller, J; Lang, A; Konrad, K; Kindermann-Glebowski, E; Seeber, A; Steiner, A; Fialla, R; Pachinger, W; Kos, C; Klein, G; Kehrer, H; Kerl, H; Ulmer, H; Smolle, J Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
BRIT J DERMATOL. 2004; 151(1): 91-98. Doi: 10.1111/j.1365-2133.2004.06019.x
Web of Science PubMed FullText FullText_MUG

 

2003

Andersen, MH; Gehl, J; Reker, S; Pedersen, LO; Becker, JC; Geertsen, P; Straten, PT Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Semin Cancer Biol. 2003; 13(6):449-459 Doi: 10.1016/j.semcancer.2003.09.009
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Richtig, E; Hoff, M; Rehak, P; Kapp, K; Hofmann-Wellenhof, R; Zalaudek, I; Poschauko, J; Uggowitzer, M; Kohek, P; Smolle, J Efficacy of superficial and deep regional hyperthermia combined with systemic chemotherapy and radiotherapy in metastatic melanoma.
J Dtsch Dermatol Ges. 2003; 1(8):635-642 Doi: 10.1046/j.1610-0387.2003.03719.x
PubMed FullText FullText_MUG Google Scholar

 

Schaider, H; Oka, M; Bogenrieder, T; Nesbit, M; Satyamoorthy, K; Berking, C; Matsushima, K; Herlyn, M Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8.
Int J Cancer. 2003; 103(3):335-343 Doi: 10.1002/ijc.10775
Web of Science PubMed FullText FullText_MUG

 

Ugurel, S; Schadendorf, D Systemic treatment in advanced melanoma: innovative perspectives.
Onkologie. 2003; 26(3):234-238 Doi: 10.1159/000071618
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Weitere 50 Treffer anzeigen
© Med Uni Graz Impressum